Health and Me

Tanya Dutt

Women With Autoimmune Diseases Face Greater Risk Of Deadly Heart Complications; How To Protect Yourself?

Autoimmune illnesses like rheumatoid arthritis (RA), lupus, and <span>systemic sclerosis</span> have long been famous for their creation of chronic inflammation and joint devastation, but new evidence is surfacing that these diseases are subtly damaging the heart—particularly among women. The study, reported in Circulation: Cardiovascular Quality and Outcomes, estimated that women who have these disorders are at 50% higher risk of heart disease-related death than men. Although progress has been made in treating autoimmune diseases, the cardiovascular dangers they pose—especially to women—are underdiagnosed and undertreated.

Autoimmune illnesses are much more common in women. Almost twice to three times as many women have RA compared to men, and with lupus, it is nine times as many. Systemic sclerosis, characterized by tightening of the skin and possible damage to internal organs, also occurs more often in women.

The higher cardiovascular death rate in women with these diseases is not just a statistical coincidence. Dr. Heba Wassif, Director of Cardio-Rheumatology at Cleveland Clinic and senior author of the study, highlights that the burden of cardiovascular disease in immune-mediated inflammatory conditions is both substantial and disproportionately impacts women. This prompts important questions about how autoimmune-driven inflammation specifically affects women's cardiovascular health—and why their risks have been so historically underestimated.

In perhaps the most thorough analysis yet, scientists sifted through data on over 281,000 deaths attributed to RA, lupus, and systemic sclerosis between 1999 and 2020. More than 127,000 of those were from heart complications.

While overall mortality rates for heart disease fell—from 3.9 to 2.1 per 100,000 among women and from 1.7 to 1.2 among men—the gap between men and women narrowed only slightly: women continued to die from heart disease at disproportionately higher rates.

Even more alarming, stroke and blocked arteries (atherosclerosis) became the leading killers of women, along with the stark rate of deaths due to irregular heart rhythms and cardiac arrest—over twice that of men.

<h2>How <span rel="noindex">Autoimmune Inflammation</span> Damages the Heart?</h2>

Autoimmune diseases induce the body to mistakenly attack its own tissues. In RA, the immune system assaults the synovium—the joint lining—leading to swelling, pain, and inflammation. But this inflammation does not end here. It can spread to essential organs, such as the heart, lungs, and blood vessels.

Chronic inflammation promotes the formation of plaque in arteries, damages the linings of blood vessels, and accelerates atherosclerosis—a key risk factor for heart attack and stroke. In addition, the systemic inflammation can provoke arrhythmias and worsen heart failure.

The same medications that treat autoimmune diseases—like corticosteroids and certain immunosuppressants—can also increase cardiovascular risks indirectly by elevating blood pressure, blood sugar, or cholesterol levels if not monitored carefully.

<h2>How Heart Diseases have Become a Leading Killer in Autoimmune Patients?</h2>

Dr. Issam Motairek, lead author of the study, points to a dramatic change in the perception of mortality among autoimmune patients. "There is a general belief that individuals with immune-mediated inflammatory diseases die mostly from infections or kidney disease," he said. "But our study found that one-third of deaths in this group were caused by cardiovascular disease."

This change points to an urgent necessity to rephrase the way we perceive autoimmune conditions—not only as musculoskeletal or cutaneous problems, but as inflammatory disorders of the whole body with lethal cardiovascular ramifications.

<h2>Ways to Control Autoimmune Flares to Keep Your Heart Safe</h2>

Most of this cardiovascular danger can be avoided. Here is the way in which women suffering from autoimmune disorders can actively shield their heart:

Early and recurrent cardiovascular screening – At the diagnosis of autoimmune disease, screening should be done by Dr. Wassif and then on a regular basis thereafter. This will include blood pressure, cholesterol, glucose levels, and inflammation markers.

Aggressive inflammation control – Treatment of RA or lupus early and effectively not only benefits the joints but also curtails systemic inflammation that can harm the heart.

Lifestyle interventions – Exercise, a heart-healthy diet, stress reduction, and smoking cessation are even more crucial in this group. Exercise may be difficult during flare-ups, but low-impact exercise such as walking or yoga can be helpful.

Weight control – Achy joints and fatigue can reduce mobility, promoting weight gain. But obesity itself is a principal cause of high blood pressure, diabetes, and heart disease—each of which multiplies the risks for autoimmune patients.

Collaborative working with healthcare providers – Rheumatologists, cardiologists, and primary care physicians must work in concert. An expert cardio-rheumatology team, such as at premier institutions like Cleveland Clinic, can provide individualized care.

Of all autoimmune conditions researched, rheumatoid arthritis carried the greatest risk of cardiovascular mortality. RA not only inflames joints—it can also cause damage to heart valves, inflammation of the heart muscle (myocarditis), and pericarditis (inflammation of the outer layer of the heart). In addition, RA is frequently accompanied by fatigue, low-grade fever, and decreased activity—all of which can conceal or exacerbate heart disease.

This seminal study should be an eye-opener for both patients and clinicians. It reinforces the need not to brush off symptoms such as palpitations, chest pain, shortness of breath, or fatigue in women with autoimmune diseases. It also highlights the imperative of greater gender-specific research and an overarching, preventive approach to autoimmune diseases—not merely for joint well-being, but for survival.

If you’re a woman living with an autoimmune inflammatory disease, protecting your heart isn't optional—it’s essential. Don’t wait for a cardiac symptom to speak up. Be your own advocate, and demand comprehensive cardiovascular care. Early detection, effective inflammation control, and lifestyle support can go a long way in reducing your risk—and adding years to your life.

Health Conditions A-Z

health

heart health

women heath

autoimmune disease in women

rheumatoid arthritis heart risk

lupus heart complications

systemic sclerosis

women heart disease

autoimmune inflammation

cardiovascular risk factors

What Is Japanese Walk—The Fitness Trend That Makes You 10 Years Younger

Valley Fever Cases Surge In California-How To Identifiy This Lung Infection

Can Yoga Make Your Lung Strong?

Health News

Must-Do Chest Exercises You Can Try At Home

What Are The Symptoms Of JN.1 COVID-19 Strain?

Why Does Sleeping Become Harder As You Age?

High-Fiber Healthy Drinks You Should Try

10 Dumbbell Exercise Variations For Upper-Body Strength

A Parent’s Guide To Pets: Important Points To Consider For Your Child’s Health

Food Anxiety Is Real – How Your Food Intake Affects Your Anxiety

World Osteoporosis Month: Ways To Strengthen Your Bones

Brain Exercises To Keep You Cognitively Sharp

Easy Recipes To Make When You Don’t Wish To Cook

Physical Signs Of High Cortisol

9 Healthy Plant-Based Protein Rich Dishes To Try

What Happens When You Have Low Blood Pressure?

Throw These Toxic Bathroom Items Away To Protect Your Health

This Is What Cricket Superstar Virat Kohli Eats In A Day

Signs You Are Experiencing Sensory Overload

Shoulder Exercises You Should Do For Defined Shoulders

Best Foods To Eat When You Are Fasting

​Ghee For Ayurveda: Why It Should Be A Part Of Your Diet​

Symptoms Of Ovarian Cancer You Should Know

Yoga Poses That Can Build Core Strength

Biotin-Rich Foods You Should Add To Your Diet

Unexpected Physical Signs Of Stress

Simple And Affective Guide To Stop A Panic Attack

Signs Of Heat Exhaustion In Children

10 Heart Symptoms You Shouldn't Ignore

Lower Your Cholesterol With These Foods

Food Myths You Should Stop Believing

Work Stressing You Out? Tips To Handle Toxic Workspaces

Looking To Gain Weight? High-Calorie Healthy Foods To Try

​Pomegranates Are A Must For Summer, Here’s Why​

​How Does Being A Night Owl Change Your Brain​

​Can Nightlights Affect Your Child’s Sleep​

How To Decide Whether You Should Do Cardio Or Strength Training?

Enjoying Hobbies As An Adult Is More Important Than You Realize

Screentime Matters For Parents Too, Here's How It Causes Issues

Why Should We Discard Expired Prescription Drugs?

Perks Of Having Home Plants For Your Health

Signs You Are Dealing With Depleted Mother Syndrome

Protein-Rich Fruit Smoothies You Must Try

Autoimmune illnesses like rheumatoid arthritis (RA), lupus, and systemic sclerosis have long been famous for their creation of chronic inflammation and joint devastation, but new evidence is surfacing that these diseases are subtly damaging the heart—particularly among women. The study, reported in Circulation: Cardiovascular Quality and Outcomes, estimated that women who have these disorders are at 50% higher risk of heart disease-related death than men. Although progress has been made in treating autoimmune diseases, the cardiovascular dangers they pose—especially to women—are underdiagnosed and undertreated.Autoimmune illnesses are much more common in women. Almost twice to three times as many women have RA compared to men, and with lupus, it is nine times as many. Systemic sclerosis, characterized by tightening of the skin and possible damage to internal organs, also occurs more often in women.The higher cardiovascular death rate in women with these diseases is not just a statistical coincidence. Dr. Heba Wassif, Director of Cardio-Rheumatology at Cleveland Clinic and senior author of the study, highlights that the burden of cardiovascular disease in immune-mediated inflammatory conditions is both substantial and disproportionately impacts women. This prompts important questions about how autoimmune-driven inflammation specifically affects women's cardiovascular health—and why their risks have been so historically underestimated.In perhaps the most thorough analysis yet, scientists sifted through data on over 281,000 deaths attributed to RA, lupus, and systemic sclerosis between 1999 and 2020. More than 127,000 of those were from heart complications.While overall mortality rates for heart disease fell—from 3.9 to 2.1 per 100,000 among women and from 1.7 to 1.2 among men—the gap between men and women narrowed only slightly: women continued to die from heart disease at disproportionately higher rates.Even more alarming, stroke and blocked arteries (atherosclerosis) became the leading killers of women, along with the stark rate of deaths due to irregular heart rhythms and cardiac arrest—over twice that of men.How Autoimmune Inflammation Damages the Heart?Autoimmune diseases induce the body to mistakenly attack its own tissues. In RA, the immune system assaults the synovium—the joint lining—leading to swelling, pain, and inflammation. But this inflammation does not end here. It can spread to essential organs, such as the heart, lungs, and blood vessels.Chronic inflammation promotes the formation of plaque in arteries, damages the linings of blood vessels, and accelerates atherosclerosis—a key risk factor for heart attack and stroke. In addition, the systemic inflammation can provoke arrhythmias and worsen heart failure.The same medications that treat autoimmune diseases—like corticosteroids and certain immunosuppressants—can also increase cardiovascular risks indirectly by elevating blood pressure, blood sugar, or cholesterol levels if not monitored carefully.How Heart Diseases have Become a Leading Killer in Autoimmune Patients?Dr. Issam Motairek, lead author of the study, points to a dramatic change in the perception of mortality among autoimmune patients. "There is a general belief that individuals with immune-mediated inflammatory diseases die mostly from infections or kidney disease," he said. "But our study found that one-third of deaths in this group were caused by cardiovascular disease."This change points to an urgent necessity to rephrase the way we perceive autoimmune conditions—not only as musculoskeletal or cutaneous problems, but as inflammatory disorders of the whole body with lethal cardiovascular ramifications.Ways to Control Autoimmune Flares to Keep Your Heart SafeMost of this cardiovascular danger can be avoided. Here is the way in which women suffering from autoimmune disorders can actively shield their heart:Early and recurrent cardiovascular screening – At the diagnosis of autoimmune disease, screening should be done by Dr. Wassif and then on a regular basis thereafter. This will include blood pressure, cholesterol, glucose levels, and inflammation markers.Aggressive inflammation control – Treatment of RA or lupus early and effectively not only benefits the joints but also curtails systemic inflammation that can harm the heart.Lifestyle interventions – Exercise, a heart-healthy diet, stress reduction, and smoking cessation are even more crucial in this group. Exercise may be difficult during flare-ups, but low-impact exercise such as walking or yoga can be helpful.Weight control – Achy joints and fatigue can reduce mobility, promoting weight gain. But obesity itself is a principal cause of high blood pressure, diabetes, and heart disease—each of which multiplies the risks for autoimmune patients.Collaborative working with healthcare providers – Rheumatologists, cardiologists, and primary care physicians must work in concert. An expert cardio-rheumatology team, such as at premier institutions like Cleveland Clinic, can provide individualized care.Of all autoimmune conditions researched, rheumatoid arthritis carried the greatest risk of cardiovascular mortality. RA not only inflames joints—it can also cause damage to heart valves, inflammation of the heart muscle (myocarditis), and pericarditis (inflammation of the outer layer of the heart). In addition, RA is frequently accompanied by fatigue, low-grade fever, and decreased activity—all of which can conceal or exacerbate heart disease.This seminal study should be an eye-opener for both patients and clinicians. It reinforces the need not to brush off symptoms such as palpitations, chest pain, shortness of breath, or fatigue in women with autoimmune diseases. It also highlights the imperative of greater gender-specific research and an overarching, preventive approach to autoimmune diseases—not merely for joint well-being, but for survival.If you’re a woman living with an autoimmune inflammatory disease, protecting your heart isn't optional—it’s essential. Don’t wait for a cardiac symptom to speak up. Be your own advocate, and demand comprehensive cardiovascular care. Early detection, effective inflammation control, and lifestyle support can go a long way in reducing your risk—and adding years to your life.

women with autoimmune diseases face greater risk of deadly heart complications; how to protect yourself?

Riya Baibhawi

Influenza Raises Heart Attack Risk By 6X– Here's Another Reason To Get Your Flu Shot

influenza raises heart attack risk by 6x– here's another reason to get your flu shot

FDA Approves New COVID Vaccine But Not Everyone Qualifies

fda approves new covid vaccine but not everyone qualifies

Health & Wellness

Severe Pneumonia Shows 'Differently' In Children, Study Reveals New Models To Help Doctors Distinguish

study reveals new models to help doctors distinguish severe pneumonia in children

Longest Covid Infection Reported Lasted 505 Days Nonstop; What Are Persistent Infections?

longest covid infection reported lasted 505 days nonstop; what are persistent infections?

California may be heading toward another record year of <span>Valley fever</span> infections, with early 2025 data already showing a troubling increase in reported cases. Health officials have confirmed over 3,100 infections across the state—figures that surpass last year’s numbers for the same period and nearly double those recorded in 2023.

 Valley fever, medically known as coccidioidomycosis, is a serious lung infection caused by the <em>Coccidioides</em> fungus, which thrives in the dry, dusty soils of the western U.S. California, where the disease was first identified, consistently reports the highest number of cases nationwide. If left untreated, the illness can lead to severe, long-term respiratory issues and even death if it spreads to the brain.

 “There is no question that the number of cases is enormously higher than before,” said Dr. Royce Johnson, director of the Valley Fever Institute at Kern Medical. “If you want to see me, you’d have to wait until July, and that goes for my colleagues, too,” he told NBC News, highlighting the growing strain on healthcare systems in affected regions.

 The majority of recent infections have been reported in Kern, Los Angeles, Monterey, and Fresno counties—areas long known as hotspots. But the illness is now expanding its reach. In Contra Costa County, located in the East Bay region, cases have tripled compared to 2023. Nearby Merced and San Bernardino counties are also reporting significant spikes.

 “It appears to be spreading out,” noted Gail Sondermeyer Cooksey, an epidemiologist with the California Department of Public Health.

 Valley fever infections occur when people inhale spores released into the air from soil containing <em>Coccidioides</em>. These spores can be stirred up by wind, construction, and agricultural activities. While anyone can get infected, those most at risk include people over 60, individuals with weakened immune systems, pregnant women, diabetics, and those of Black or Filipino descent. Outdoor workers also face higher exposure.

 Symptoms typically resemble those of the flu and may include fatigue, cough, fever, shortness of breath, and skin rashes. While most recover, about 10 percent develop chronic lung issues, and approximately 1 percent experience dissemination of the infection to the skin, bones, joints, or brain.

 Health experts also point to a concerning link between <strong>climate change</strong> and the disease's rising prevalence. Shifts from prolonged drought to intense rain—common in California’s recent weather patterns—create favorable conditions for the fungus to grow and later release spores as the land dries.

 “As climate change alters the timing and intensity of precipitation in California, we see longer high-risk periods for <em>Coccidioides</em> exposure,” said Simon Camponuri, a PhD researcher at the University of California, Berkeley.

 With forecasts predicting a hot and dry summer following recent floods and mudslides, health officials are bracing for continued spikes in Valley fever cases in the coming months. Public health campaigns are urging increased awareness, especially among vulnerable populations and those living in high-risk regions.

Valley Fever

US Health News

Valley Fever symptoms

How To Identify Valley Fever

California valley fever

California may be heading toward another record year of Valley fever infections, with early 2025 data already showing a troubling increase in reported cases. Health officials have confirmed over 3,100 infections across the state—figures that surpass last year’s numbers for the same period and nearly double those recorded in 2023. Valley fever, medically known as coccidioidomycosis, is a serious lung infection caused by the Coccidioides fungus, which thrives in the dry, dusty soils of the western U.S. California, where the disease was first identified, consistently reports the highest number of cases nationwide. If left untreated, the illness can lead to severe, long-term respiratory issues and even death if it spreads to the brain. “There is no question that the number of cases is enormously higher than before,” said Dr. Royce Johnson, director of the Valley Fever Institute at Kern Medical. “If you want to see me, you’d have to wait until July, and that goes for my colleagues, too,” he told NBC News, highlighting the growing strain on healthcare systems in affected regions. The majority of recent infections have been reported in Kern, Los Angeles, Monterey, and Fresno counties—areas long known as hotspots. But the illness is now expanding its reach. In Contra Costa County, located in the East Bay region, cases have tripled compared to 2023. Nearby Merced and San Bernardino counties are also reporting significant spikes. “It appears to be spreading out,” noted Gail Sondermeyer Cooksey, an epidemiologist with the California Department of Public Health. Valley fever infections occur when people inhale spores released into the air from soil containing Coccidioides. These spores can be stirred up by wind, construction, and agricultural activities. While anyone can get infected, those most at risk include people over 60, individuals with weakened immune systems, pregnant women, diabetics, and those of Black or Filipino descent. Outdoor workers also face higher exposure. Symptoms typically resemble those of the flu and may include fatigue, cough, fever, shortness of breath, and skin rashes. While most recover, about 10 percent develop chronic lung issues, and approximately 1 percent experience dissemination of the infection to the skin, bones, joints, or brain. Health experts also point to a concerning link between climate change and the disease's rising prevalence. Shifts from prolonged drought to intense rain—common in California’s recent weather patterns—create favorable conditions for the fungus to grow and later release spores as the land dries. “As climate change alters the timing and intensity of precipitation in California, we see longer high-risk periods for Coccidioides exposure,” said Simon Camponuri, a PhD researcher at the University of California, Berkeley. With forecasts predicting a hot and dry summer following recent floods and mudslides, health officials are bracing for continued spikes in Valley fever cases in the coming months. Public health campaigns are urging increased awareness, especially among vulnerable populations and those living in high-risk regions.

valley fever cases surge in california-how to identifiy this lung infection

GLP-1 Drugs Fight Fat, Curb Appetite And May Also Reduce Cancer Risk

Nutrition

Ozempic Without The Side Effects? Try This Drug-Free Method

ozempic without the side effects? try this drug-free method

Losing Weight= Losing Health? Ozempic Risks You Can’t Afford To Ignore

losing weight= losing health? ozempic risks you can’t afford to ignore

Joe Biden Is Diagnosed With Aggressive Prostate Cancer: All That You Need To Know

joe biden is diagnosed with aggressive prostate cancer: all that you need to know

About 2 Out Of 5 Heart Failure Patients Don’t See A Cardiologist Even Once A Year

about 2 out of 5 heart failure patients don’t see a cardiologist even once a year

What if the one injection that is helping you lose weight and manage diabetes also protect you from <span>cancer</span>? That's the surprising promise emerging from a new study on <span>GLP-1 drugs</span>, drugs already drawing attention for their ability to battle obesity and regulate blood sugar. Now scientists have discovered a potential new advantage: a much reduced risk of cancers related to obesity.

While the global use of GLP-1 agonists such as Saxenda and Byetta is gaining speed, this research unlocks a thrilling new era in preventive care. But just how do such medications function and why could they be protecting us against cancer?

After once being touted as miracle drugs for treating obesity and type 2 diabetes, GLP-1 medications such as Saxenda and Byetta are now uncovering a new benefit: a reduced risk of cancer. New research in the journal eClinicalMedicine identifies that these initial weight-loss medications may have more to their credit than just reducing waistlines—they can cut the risk of developing obesity-linked cancers by a dramatic 41%.

This finding has the potential to change forever the way that we think about the wider ramifications of GLP-1 treatments, particularly in a world where metabolic diseases are closely associated with cancer susceptibility. But why might this new benefit exist? And how do these drugs actually work?

<h2>What Are GLP-1 Drugs and How Do They Work?</h2>

GLP-1 agonists (glucagon-like peptide-1 receptor agonists) are a type of drug that mimics the effect of an endogenous hormone involved in the modulation of appetite, blood glucose levels, and digestion. Initially approved for the treatment of type 2 diabetes, they've become very popular due to their capacity to cause weight loss by reducing hunger and slowing gastric emptying.

Drugs such as liraglutide (Saxenda) and exenatide (Byetta) are usually given through subcutaneous injection. Newer forms, including semaglutide (<span>Ozempic</span>) and tirzepatide (Zepbound), have greater efficacy in weight loss and metabolic control, although they were not part of this specific study.

GLP-1 acts via a cascade of hormonal action:

<ul><li>It triggers the release of insulin from the pancreas, lowering blood sugar.</li><li>It inhibits the release of glucagon, a hormone that increases blood sugar.</li><li>It reduces the rate at which the stomach empties following meals.</li></ul>

Perhaps most importantly for managing weight, it sends satiety messages to the brain to make people feel fuller for longer.

<h2>Missing Link Between Cancer Risk and Obesity </h2>

Both type 2 diabetes and obesity are firmly established as risk factors for many forms of cancer, such as breast, colon, uterine, pancreatic, and liver cancer. This can be explained by the chronic inflammation, insulin resistance, and hormonal imbalance that accompany excess fat stores.

For their new study, scientists from Clalit Health Services in Tel Aviv, Israel, analyzed electronic health records of more than 6,300 adults age 24 and above. Everyone involved had both type 2 diabetes and obesity and received either GLP-1 medication or weight-loss surgery between 2010 and 2018. The group was followed through to December 2023 to record cancer diagnoses.

During a median follow-up of 7.5 years, approximately 300 individuals developed cancer of the obesity type—predominantly breast (26%), colon (16%), and uterus (15%).

Although bariatric surgery has been the obesity treatment gold standard for decades—and was in turn found to lower cancer risk—scientists discovered obesity-associated cancers were equal in both the surgery and GLP-1 groups. This was unexpected because surgery tends to induce greater and more immediate weight loss.

Still, additional statistical examination found that the GLP-1 medications offered a 41% lower risk of cancerous developments than surgery indicated that their anti-cancer benefit might extend beyond weight loss alone.

<h2>Reason Behind the Anti-Cancer Effect</h2>

According to co-lead researcher Dr. Dror Dicker, who heads the Obesity Clinic at Hasharon Hospital-Rabin Medical Center, the anti-cancer effects of GLP-1 drugs likely stem from multiple mechanisms. “Reducing inflammation, improving insulin sensitivity, and altering cellular growth pathways may all play a role,” he noted in a news release.

While more recent, more powerful GLP-1 medications such as Ozempic and Zepbound were not included in the study, researchers are convinced they may provide even stronger protective effects. However, additional long-term studies are necessary to determine their impacts on cancers that are not related to obesity.

This new evidence indicates a paradigm shift of foundational importance in the way we think about metabolic health interventions. GLP-1 medications could soon be hailed not merely as weight-loss supplements or treatments for diabetes but as prevention against one of the world's most dreaded illnesses.

Nevertheless, prudence is still advisable. Long-term experience with these drugs is lacking, and their side effects, including nausea, gastrointestinal upset, and possible hazards for thyroid tumors, need to be weighed. A boxed warning is now placed on the list of the FDA for some GLP-1 drugs for thyroid C-cell tumors, although this has so far been seen most commonly in animal models.

With the worldwide obesity epidemic on the rise, so is the need to know how drugs such as GLP-1 agonists can change not only waistlines, but also long-term health endpoints. The notion that a single class of medication might lower the risk of cancer in addition to managing blood glucose and reducing appetite is revolutionary.

Additional research, particularly with next-generation GLP-1 drugs, will be necessary to more fully investigate and validate these benefits but for the time being, this study introduces an exhilarating and promising new chapter at the nexus of <span>cancer prevention</span> and obesity treatment.

cancer

glp-1 drugs

cancer prevention

weight loss medication

obesity-related cancer

saxenda study

glp-1 cancer risk

diabetes and cancer

ozempic

What if the one injection that is helping you lose weight and manage diabetes also protect you from cancer? That's the surprising promise emerging from a new study on GLP-1 drugs, drugs already drawing attention for their ability to battle obesity and regulate blood sugar. Now scientists have discovered a potential new advantage: a much reduced risk of cancers related to obesity.While the global use of GLP-1 agonists such as Saxenda and Byetta is gaining speed, this research unlocks a thrilling new era in preventive care. But just how do such medications function and why could they be protecting us against cancer?After once being touted as miracle drugs for treating obesity and type 2 diabetes, GLP-1 medications such as Saxenda and Byetta are now uncovering a new benefit: a reduced risk of cancer. New research in the journal eClinicalMedicine identifies that these initial weight-loss medications may have more to their credit than just reducing waistlines—they can cut the risk of developing obesity-linked cancers by a dramatic 41%.This finding has the potential to change forever the way that we think about the wider ramifications of GLP-1 treatments, particularly in a world where metabolic diseases are closely associated with cancer susceptibility. But why might this new benefit exist? And how do these drugs actually work?What Are GLP-1 Drugs and How Do They Work?GLP-1 agonists (glucagon-like peptide-1 receptor agonists) are a type of drug that mimics the effect of an endogenous hormone involved in the modulation of appetite, blood glucose levels, and digestion. Initially approved for the treatment of type 2 diabetes, they've become very popular due to their capacity to cause weight loss by reducing hunger and slowing gastric emptying.Drugs such as liraglutide (Saxenda) and exenatide (Byetta) are usually given through subcutaneous injection. Newer forms, including semaglutide (Ozempic) and tirzepatide (Zepbound), have greater efficacy in weight loss and metabolic control, although they were not part of this specific study.GLP-1 acts via a cascade of hormonal action:It triggers the release of insulin from the pancreas, lowering blood sugar.It inhibits the release of glucagon, a hormone that increases blood sugar.It reduces the rate at which the stomach empties following meals.Perhaps most importantly for managing weight, it sends satiety messages to the brain to make people feel fuller for longer.Missing Link Between Cancer Risk and Obesity Both type 2 diabetes and obesity are firmly established as risk factors for many forms of cancer, such as breast, colon, uterine, pancreatic, and liver cancer. This can be explained by the chronic inflammation, insulin resistance, and hormonal imbalance that accompany excess fat stores.For their new study, scientists from Clalit Health Services in Tel Aviv, Israel, analyzed electronic health records of more than 6,300 adults age 24 and above. Everyone involved had both type 2 diabetes and obesity and received either GLP-1 medication or weight-loss surgery between 2010 and 2018. The group was followed through to December 2023 to record cancer diagnoses.During a median follow-up of 7.5 years, approximately 300 individuals developed cancer of the obesity type—predominantly breast (26%), colon (16%), and uterus (15%).GLP-1 vs. SurgeryAlthough bariatric surgery has been the obesity treatment gold standard for decades—and was in turn found to lower cancer risk—scientists discovered obesity-associated cancers were equal in both the surgery and GLP-1 groups. This was unexpected because surgery tends to induce greater and more immediate weight loss.Still, additional statistical examination found that the GLP-1 medications offered a 41% lower risk of cancerous developments than surgery indicated that their anti-cancer benefit might extend beyond weight loss alone.Reason Behind the Anti-Cancer EffectAccording to co-lead researcher Dr. Dror Dicker, who heads the Obesity Clinic at Hasharon Hospital-Rabin Medical Center, the anti-cancer effects of GLP-1 drugs likely stem from multiple mechanisms. “Reducing inflammation, improving insulin sensitivity, and altering cellular growth pathways may all play a role,” he noted in a news release.While more recent, more powerful GLP-1 medications such as Ozempic and Zepbound were not included in the study, researchers are convinced they may provide even stronger protective effects. However, additional long-term studies are necessary to determine their impacts on cancers that are not related to obesity.Can It Change Cancer Treatment?This new evidence indicates a paradigm shift of foundational importance in the way we think about metabolic health interventions. GLP-1 medications could soon be hailed not merely as weight-loss supplements or treatments for diabetes but as prevention against one of the world's most dreaded illnesses.Nevertheless, prudence is still advisable. Long-term experience with these drugs is lacking, and their side effects, including nausea, gastrointestinal upset, and possible hazards for thyroid tumors, need to be weighed. A boxed warning is now placed on the list of the FDA for some GLP-1 drugs for thyroid C-cell tumors, although this has so far been seen most commonly in animal models.With the worldwide obesity epidemic on the rise, so is the need to know how drugs such as GLP-1 agonists can change not only waistlines, but also long-term health endpoints. The notion that a single class of medication might lower the risk of cancer in addition to managing blood glucose and reducing appetite is revolutionary.Additional research, particularly with next-generation GLP-1 drugs, will be necessary to more fully investigate and validate these benefits but for the time being, this study introduces an exhilarating and promising new chapter at the nexus of cancer prevention and obesity treatment.

glp-1 drugs fight fat, curb appetite and may also reduce cancer risk

Not Cholesterol: Surprising Chemical In Shampoo Bottles Tied To Heart-Related Deaths In India

Plastic Pieces Prompt Recall Of Popular Ice Cream Brand

plastic pieces prompt recall of popular ice cream brand

Fitness

Does The Requirement Of Exercising Impact On One's Gender?

does the requirement of exercising impact on one's gender?

High Cholesterol Linked To Longer Life Spans In This Blue Zone

high cholesterol linked to longer life spans in this blue zone

Thousands of Indians die every year from heart disease. Now you may link it to high cholesterol and a lack of physical exercise, but the reality is different. According to researchers, these deaths are a result of exposure to a harmful chemical that is present in shampoos, food containers and all other common household <span>plastic</span> products. 

A recent study published in The Lancet eBioMedicine has identified a significant link between exposure to di-2-ethylhexyl <span>phthalate</span> (DEHP)—a chemical commonly used to make plastics more flexible—and heart disease deaths. Surprisingly, among the 200 countries evaluated, India had the highest burden of DEHP-linked cardiovascular deaths and accounted for almost a third of the global mortalities.

DEHP is prevalent in numerous household items, including food containers, medical equipment, toys, shampoos and lotions. The study, conducted by researchers at NYU Langone Health, analysed urine samples and environmental data from over 200 countries and territories. They found that in 2018, DEHP exposure was associated with around 356,238 deaths among individuals aged 55 to 64, accounting for over 13 per cent of global heart disease deaths in that age group. The researchers attributed India's elevated mortality to the rapid expansion of its plastics industry, widespread use of DEHP-containing products and weaker regulatory controls compared to some other nations. 

It is estimated that chemicals in plastic were linked to nearly 350,000 heart disease deaths across the world in 2018. Adding to that, is this study published in the journal eBioMedicine, which estimated that roughly 13 per cent of cardiovascular deaths among 55- to 64-year-olds worldwide that year could be attributed to phthalates.

Where Are Phthalates are esters of phthalic acids, which are added to plastics to increase their flexibility, transparency, durability, and longevity. They are found in personal care products like shampoos and lotions as well as in food containers and packaging. It is also possible to ingest them through food, absorb them through skin from products containing them or breathe them from dust.

<h2>Study Shows Phthalates Increase Risk of Heart Diseases</h2>

Some studies have shown an association between phthalates and cardiovascular disease, but there isn’t strong evidence to show that the chemicals directly cause heart issues, said Sung Kyun Park, a professor of epidemiology and environmental sciences at the University of Michigan School of Public Health. However, there is enough evidence that states that phthalates increase the risk of metabolic disorders like obesity and Type 2 diabetes, which can cause cardiovascular disease. One way phthalates may do this is by increasing oxidative stress—cell and tissue damage that happens when there are too many unstable molecules in the body—and by promoting inflammation. 

Cardiovascular Diseases

Plastic

Deaths due to plastic

Phthalate

Health issues in India

Thousands of Indians die every year from heart disease. Now you may link it to high cholesterol and a lack of physical exercise, but the reality is different. According to researchers, these deaths are a result of exposure to a harmful chemical that is present in shampoos, food containers and all other common household plastic products. A recent study published in The Lancet eBioMedicine has identified a significant link between exposure to di-2-ethylhexyl phthalate (DEHP)—a chemical commonly used to make plastics more flexible—and heart disease deaths. Surprisingly, among the 200 countries evaluated, India had the highest burden of DEHP-linked cardiovascular deaths and accounted for almost a third of the global mortalities.What Is DEHP?DEHP is prevalent in numerous household items, including food containers, medical equipment, toys, shampoos and lotions. The study, conducted by researchers at NYU Langone Health, analysed urine samples and environmental data from over 200 countries and territories. They found that in 2018, DEHP exposure was associated with around 356,238 deaths among individuals aged 55 to 64, accounting for over 13 per cent of global heart disease deaths in that age group. The researchers attributed India's elevated mortality to the rapid expansion of its plastics industry, widespread use of DEHP-containing products and weaker regulatory controls compared to some other nations. It is estimated that chemicals in plastic were linked to nearly 350,000 heart disease deaths across the world in 2018. Adding to that, is this study published in the journal eBioMedicine, which estimated that roughly 13 per cent of cardiovascular deaths among 55- to 64-year-olds worldwide that year could be attributed to phthalates.Where Are Phthalates are esters of phthalic acids, which are added to plastics to increase their flexibility, transparency, durability, and longevity. They are found in personal care products like shampoos and lotions as well as in food containers and packaging. It is also possible to ingest them through food, absorb them through skin from products containing them or breathe them from dust.Study Shows Phthalates Increase Risk of Heart DiseasesSome studies have shown an association between phthalates and cardiovascular disease, but there isn’t strong evidence to show that the chemicals directly cause heart issues, said Sung Kyun Park, a professor of epidemiology and environmental sciences at the University of Michigan School of Public Health. However, there is enough evidence that states that phthalates increase the risk of metabolic disorders like obesity and Type 2 diabetes, which can cause cardiovascular disease. One way phthalates may do this is by increasing oxidative stress—cell and tissue damage that happens when there are too many unstable molecules in the body—and by promoting inflammation. 

not cholesterol: surprising chemical in shampoo bottles tied to heart-related deaths in india

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Women With Autoimmune Diseases Face Greater Risk Of Deadly Heart Complications; How To Protect Yourself?

Quick Stories

Valley Fever Cases Surge In California-How To Identifiy This Lung Infection

GLP-1 Drugs Fight Fat, Curb Appetite And May Also Reduce Cancer Risk

Not Cholesterol: Surprising Chemical In Shampoo Bottles Tied To Heart-Related Deaths In India

Health Conditions A-Z

What Is Japanese Walk—The Fitness Trend That Makes You 10 Years Younger

Valley Fever Cases Surge In California-How To Identifiy This Lung Infection

Can Yoga Make Your Lung Strong?